The Alzheimer’s Agitation and Psychosis Report
Agitation and psychosis are increasingly recognized as distinct and clinically significant neuropsychiatric syndromes in Alzheimer’s disease, yet remain areas of substantial unmet medical need.
This Report Offers Insight Into:
- The extent of unmet medical need and treatment limitations in Alzheimer’s disease agitation and psychosis.
- The current pipeline and developer landscape, including which mechanisms of action and targets are being prioritized.
- The availability and maturity of preclinical and clinical evidence across agitation and psychosis, as well as upcoming development milestones.
You May Also Be Interested In…
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
